Loading...
Market
How will AstraZeneca stock perform relative to the sector by end of Q1 2025?
2
Resolution / Starting Odds
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Stock market data and financial analysis reports
Story
AstraZeneca's China President and EVP Leon Wang Under Investigation; Shares Drop 3.5%
Oct 30, 2024, 02:00 PM
AstraZeneca announced at 9:00am that its China President and Executive Vice President of International, Leon Wang, is currently under investigation by Chinese authorities and is cooperating with the inquiry. The company's China operations will continue under the leadership of the current general manager. Following the announcement, AstraZeneca's shares dropped by 3.5%.
View original story
Similar markets
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%
Stock price increases by more than 10% • 25%
Stock price increases by 5-10% • 25%
Stock price remains within +/- 5% • 25%
Stock price decreases by more than 5% • 25%
Yes • 50%
No • 50%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%
Above $50 • 25%
$30 to $50 • 25%
$10 to $30 • 25%
Below $10 • 25%
No change • 25%
Improved by 1-5 ranks • 25%
Improved by 6-10 ranks • 25%
Improved by more than 10 ranks • 25%
Outperform the FTSE 100 by more than 5% • 25%
Outperform the FTSE 100 by up to 5% • 25%
Underperform the FTSE 100 by up to 5% • 25%
Underperform the FTSE 100 by more than 5% • 25%
Technology • 25%
Energy • 25%
Financials • 25%
Healthcare • 25%
Outperform • 25%
Underperform • 25%
Match performance • 25%
Significantly underperform • 25%
Outperforms sector • 25%
Performs in line with sector • 25%
Underperforms sector • 25%
Significant volatility • 25%